Vanguard Capital Management
MBRX icon

Vanguard Capital Management’s Moleculin Biotech MBRX Stock Holding History

Vanguard Capital Management’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$21.1K Hold
2,111
– – ﹤0.01% 3980
2026
Q2 		$118K Buy
2,111
+1,418
+205% +$72.4K ﹤0.01% 3866
2026
Q1 		$31.8K Buy
+693
New +$45.9K ﹤0.01% 3957

Other funds holding MBRX

Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
HRT Financial
HRT Financial New York $57.2B AUM 52.85% 1-Year Est. Return
Stratos Wealth Partners
Stratos Wealth Partners Beachwood, Ohio $9.8B AUM 20.15% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $68.5B AUM 24.33% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $273B AUM 15.34% 1-Year Est. Return
Newbridge Financial Services Group
Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

Vanguard Capital Management's MBRX Position: Q3 2026 in Review

Vanguard Capital Management held its Moleculin Biotech (MBRX) position steady in Q3 2026 at 2,111 shares worth $21.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3980.

Vanguard Capital Management first reported a position in MBRX in Q1 2026 and has held it in 3 quarters since. The position peaked at $118K in Q2 2026. 13 funds tracked by Wall St. Rank hold MBRX as of Q3 2026.

  • Vanguard Capital Management held 2,111 shares of Moleculin Biotech worth $21.1K as of Q3 2026.
  • Vanguard Capital Management left its Moleculin Biotech share count unchanged in Q3 2026.
  • Moleculin Biotech made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3980 holding.
  • Vanguard Capital Management first reported a position in Moleculin Biotech in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Moleculin Biotech position peaked at $118K in Q2 2026.
  • 13 funds tracked by Wall St. Rank held Moleculin Biotech as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.